|
Addex Pharmaceuticals discovers and develops allosteric modulators for human health. Allosteric modulators are a different kind of orally available small molecule therapeutic agent, which we believe will offer a competitive advantage over classical drugs. The lead product in our pipeline, ADX10059, has achieved clinical proof of concept and is in Phase IIb testing for the treatment of GERD (e.g. heartburn) and, separately, migraine headache. Both are important diseases for which existing products have established multi-billion dollar markets despite sub-optimal efficacy. ADX10059 is a first-in-class mGluR5 inhibitor, a therapeutic strategy that also is being pursued for multiple indications by large pharma competitors.
selected press releases
|